Mayfield (company)

World's First Gigaton-Scale Carbon Removal Company, Deep Sky, Welcomes Ron Hirson as Corporate Development Advisor

Retrieved on: 
Wednesday, September 27, 2023
IPO, AT, Atmosphere, Marketing, DocuSign, Deep-Sky Planner, Carbon, Environmental studies, Mayfield (company), Climate change, Khosla Ventures, Intel, Growth, UCLA, IPO underpricing algorithm, Fundbox, Cryptocurrency, Renewable energy, Deep-sky object

MONTRÉAL, Sept. 27, 2023 /PRNewswire/ -- Deep Sky , a Montreal-based carbon removal project developer, today announced that Ron Hirson will become a corporate development advisor to the company.

Key Points: 
  • MONTRÉAL, Sept. 27, 2023 /PRNewswire/ -- Deep Sky , a Montreal-based carbon removal project developer, today announced that Ron Hirson will become a corporate development advisor to the company.
  • At Deep Sky, Ron will advise on growth, strategy and business development, facilitating strategic partnerships with top tier talent, influencers, investors and partners.
  • Most recently, Ron served as Chief Product Officer at DocuSign (NASDAQ: DOCU), leading product and customer experience.
  • "Over the years, I've met many promising climate tech founders," said Ron Hirson, Deep Sky Advisor.

InfluxData Closes Series E Round and Raises $81 Million in Capital, Strengthens Position as Leading Time Series Provider

Retrieved on: 
Wednesday, February 8, 2023
Software, Technology, Artificial Intelligence, Data Management, Cloud, Fortune 500, IBM, Cisco, PTC, Acceleration, General partnership, Battery Ventures, Hulu, Norwest Venture Partners, Mayfield (company), Database, Series, Tesla, Citibank, RedMonk, Silicon Valley Bank, Growth, Sapphire Ventures, AI, InfluxDB, Video game, Nest

The Series E financing brings InfluxData’s total equity funding raised to $171 million.

Key Points: 
  • The Series E financing brings InfluxData’s total equity funding raised to $171 million.
  • Time series data preserves that context in a usable format to anticipate and determine trends over time.
  • As the world becomes more instrumented, applications, sensors, and systems emit a relentless stream of time series data that, when collected and analyzed, delivers valuable real-time insights.
  • “InfluxData stands out as the time series leader, delivering real-time analytics at market-shaping scale with its new database engine.

Mission Bio and Abiosciences Partner to Co-develop Bioinformatics for Clinical Research Applications in China

Retrieved on: 
Wednesday, December 28, 2022
Tao, Mortality, City, Patient, Cell, Leukemia, Neoplasm, SAN, Biotechnology, Mining, Health, Gene, Partnership, AI, Institute for Stem Cell Science and Regenerative Medicine, Diagnosis, B cell, Clinical trial, Hospital, DNA, Mayfield (company), Disease resistance, Multimedia, Hematological Cancer Research Investment and Education Act, Biomarker, Therapy, Agilent Technologies, Algorithm, HIV disease progression rates, Doctor of Philosophy, Society, Memorial Sloan Kettering Cancer Center, ASH, MRD, Cancer, Summit, Disease, Vaccine, Pharmaceutical industry, Medical device, Science

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers. The goal is to combine Mission Bio's industry-leading single-cell DNA and multi-omics capabilities with Abiosciences' cutting-edge artificial intelligence expertise, to uncover new disease signatures and address therapeutic resistance. These new capabilities can be leveraged in patient stratification for clinical trials and potentially, as a companion diagnostic tool.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 28, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers.
  • These new capabilities can be leveraged in patient stratification for clinical trials and potentially, as a companion diagnostic tool.
  • Mission Bio's Tapestri® Platform is a powerful tool that has been adopted increasingly for translational research and clinical trials, both at biopharma companies and in academia.
  • Mission Bio will support Abiosciences with its unique Tapestri single-cell multi-omics platform, custom panels, subject matter experts, and R&D expertise.

LexCheck Secures $17M Series A Led By Mayfield Fund

Retrieved on: 
Wednesday, December 14, 2022
Lawyer, ROI, Specialization, Biology, Intelligence, Initial public offering, Risk, Growth, Engineering, Bio-Rad Laboratories, Mayfield (company), Friction, Associate, Organization, Risk management

NEW YORK, Dec. 14, 2022 /PRNewswire/ -- LexCheck, the leading AI-powered contract acceleration and intelligence platform, announced today it has raised $17M in Series A funding led by Mayfield Fund. The funding will fuel the expansion of LexCheck's trusted contract review technology as it helps businesses accelerate growth by unlocking legal talent.

Key Points: 
  • NEW YORK, Dec. 14, 2022 /PRNewswire/ -- LexCheck , the leading AI-powered contract acceleration and intelligence platform, announced today it has raised $17M in Series A funding led by Mayfield Fund.
  • LexCheck has seen success with customers across more than 14 different industries, including some of the world's largest financial institutions, fastest-growing technology providers and top law firms.
  • LexCheck users are reducing time spent reviewing contracts by up to 90% and time to contract execution, oftentimes by days.
  • "LexCheck is leveraging AI to accelerate efficient revenue growth for businesses while mitigating risk," said Rajeev Batra, Partner, at Mayfield Fund.

Mission Bio partners with global pharma and academic institutions to demonstrate Tapestri® Platform's translational utility for precision therapeutics at ASH

Retrieved on: 
Wednesday, December 7, 2022
Multiomics, Therapy, Exposition, B cell, Measure (mathematics), Ernest, Assay, Azacitidine, Single cell, Society, Patient, DNA, Cancer, Agilent Technologies, MSK, Memorial Sloan Kettering Cancer Center, HIV disease progression rates, Tablet, AML, CAR, Booth, University, Children's Art Project at The University of Texas MD Anderson Cancer Center, Health, MRD, ASH, Mayfield (company), Pharmaceutical industry, Franses Tapestry Archive, Laboratoires Servier

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and multiple biopharma and academic partners are presenting data from the company's Tapestri® Platform on a range of topics at the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, beginning this weekend in New Orleans, LA. In all, Mission Bio and its partners will share 15 heme-oncology topics highlighting the use of single-cell DNA + protein multi-omics to better understand resistance mechanisms and drivers of relapse, improve identification of Measurable Residual Disease (MRD), and precisely characterize CAR T cell therapies.  These include presentations from Servier Pharmaceuticals and researchers at Memorial Sloan Kettering Cancer Center (MSK) that demonstrate Tapestri's® ability to bridge the gap between translational research and precision therapeutics, providing a deeper understanding of the patient journey and unlocking novel therapeutic approaches. These include the following:

Key Points: 
  • Researchers identified potential mechanisms of acquired resistance in patients with IDH1-mutated acute myeloid leukemia (AML) using single-cell DNA sequencing with Tapestri.
  • "Mission Bio has led the way into a new era for precision therapeutics with single-cell DNA + protein multi-omics," said Todd Druley, Chief Medical Officer at Mission Bio.
  • Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health.
  • Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution.

Mission Bio's single-cell transduction assay adopted for AVROBIO's gene therapy pipeline

Retrieved on: 
Tuesday, November 29, 2022
Environment, SAN, Cell, Chemistry, Molecular biology, CMC, DNA, IND, Patient, Institute of Analytical Sciences, Mayfield (company), CGMP, Glycogen storage disease, B cell, GMP, Cancer, Health, Therapy, NGS, Investigational New Drug, Agilent Technologies, Safety, Vaccine, Fine chemical, Pharmaceutical industry, Tapestry, Inc.

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the first-time deployment of one single-cell transduction assay across gene therapy company AVROBIO's lysosomal disorder pipeline. The two companies collaborated to develop a precise, reproducible assay using Mission Bio's Tapestri® Platform to rapidly measure the percentage of transduced cells in samples composed of thousands of cells. AVROBIO is presenting data today on the use of this assay to determine percent transduction in autologous, lentiviral vector-mediated, genetically modified drug product at the 4th Annual Gene Therapy Analytical Development (GTAD) Summit.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 /PRNewswire/ --Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the first-time deployment of one single-cell transduction assay across gene therapy company AVROBIO's lysosomal disorder pipeline.
  • AVROBIO is presenting data today on the use of this assay to determine percent transduction in autologous, lentiviral vector-mediated, genetically modified drug product at the 4th Annual Gene Therapy Analytical Development (GTAD) Summit.
  • Transduction percentage is a critical quality attribute for cell and gene therapy manufacturing, measuring the successful transduction of therapeutic genes into target cells.
  • "Because we developed the assay agnostic to particular drug products, we can integrate it across multiple programs in our pipeline.

Kofax Earns Three TrustRadius 2022 Best Software Awards

Retrieved on: 
Tuesday, November 15, 2022
Professional Services, Business, Technology, Small Business, Data Analytics, Software, Workforce, ESG, Carbon, PDF, Senior, RPA, Multimedia, Kofax, Mayfield (company), Small business, Software, Growth, Organization, Research, Video game, Typesetting, Management, Online shopping

Kofax , a leading supplier of Intelligent Automation software for digital workflow transformation, has been recognized by TrustRadius on its first annual Best Software List.

Key Points: 
  • Kofax , a leading supplier of Intelligent Automation software for digital workflow transformation, has been recognized by TrustRadius on its first annual Best Software List.
  • Based on verified reviews and customer satisfaction from B2B users, Kofaxs Power PDF received three 2022 Best Software Awards Overall Best Software, Best Software for Mid-Sized Businesses and Best Software for Small Businesses.
  • View the full release here: https://www.businesswire.com/news/home/20221115005050/en/
    Based on verified reviews and customer satisfaction from B2B users, Kofaxs Power PDF received three 2022 Best Software Awards Overall Best Software, Best Software for Mid-Sized Businesses and Best Software for Small Businesses.
  • Kofax Power PDF was selected for the 2022 Best Software List as best suited for mid-sized and small businesses, said Megan Headley, Vice President of Research at TrustRadius.

Winners of the 4th Annual UCSF | Health Hub: Digital Health Awards Announced

Retrieved on: 
Monday, November 21, 2022
Conference, Digital, Dell Technologies, VC, Organization, Partnership, Health care, CIO, Rising Star, Partner, NEA, 1Life Healthcare, Sudarshani Fernandopulle, Mayfield (company), Cleveland Clinic, Medical device, MD, Genentech

The winners were announced at a celebration at the Zouk Nightclub in Resorts World during the annual HLTH Conference in front of 1,500 guests.

Key Points: 
  • The winners were announced at a celebration at the Zouk Nightclub in Resorts World during the annual HLTH Conference in front of 1,500 guests.
  • "On behalf of the HLTH team, having the UCSF Health Hub Awards at HLTH was a great partnership between our organizations.
  • The energy around the awards program on top of the energy surrounding HLTH brought the leaders of the health innovation community together," said Nancy Mastroianni, Head of Growth for HLTH.
  • Produced by UCSFHealth Hub, the Digital Health Awards, now in its 4th year, is the leading awards show in the health tech industry awarding the next best products and technologies in the digital health space.

Vena Complete Planning Wins TrustRadius 2022 Best Software Award

Retrieved on: 
Wednesday, November 9, 2022
Organization, Review, Growth, Overalls, Budget, EPM, Microsoft, Software as a service, Mayfield (company), Forecasting, CEO, CPM, Business performance management, Finance, Completeness, Marketing, Research, Solution, Technology, Online shopping, Management, Risk management, Public relations, Facebook

TORONTO, Nov. 9, 2022 /PRNewswire/ -- Vena, the Complete Planning platform loved by finance and trusted by business, today announced that it has earned a badge for landing on the Overall TrustRadius Best Software List as well as the For Enterprise List and For Mid-Sized List, based on customer satisfaction, performance reviews and market size fit. The recognition comes on the heels of Vena winning a TrustRadius Tech Cares Award for the third consecutive year.

Key Points: 
  • The recognition comes on the heels of Vena winning a TrustRadius Tech Cares Award for the third consecutive year.
  • The TrustRadius Best Software List celebrates products that support the evolution of self-serve buyers by sourcing and using customer reviews.
  • "Vena Solutions was selected for the 2022 Best Software List as best suited for mid-sized and enterprise businesses," said Megan Headley, Vice President of Research at TrustRadius.
  • Vena Complete Planning automates planning processes across departments and systems in human resources, marketing and sales, each of which can benefit from enterprise performance management (EPM) for forecasting, budgeting and reporting, revenue planning, workforce planning, scenario analysis and beyond.

Vena Complete Planning Wins TrustRadius 2022 Best Software Award

Retrieved on: 
Wednesday, November 9, 2022
Organization, Review, Growth, Overalls, Budget, EPM, Microsoft, Software as a service, Mayfield (company), Forecasting, CEO, CPM, Business performance management, Finance, Completeness, Marketing, Research, Solution, Technology, Online shopping, Management, Risk management, Public relations, Facebook

TORONTO, Nov. 9, 2022 /PRNewswire/ -- Vena, the Complete Planning platform loved by finance and trusted by business, today announced that it has earned a badge for landing on the Overall TrustRadius Best Software List as well as the For Enterprise List and For Mid-Sized List, based on customer satisfaction, performance reviews and market size fit. The recognition comes on the heels of Vena winning a TrustRadius Tech Cares Award for the third consecutive year.

Key Points: 
  • The recognition comes on the heels of Vena winning a TrustRadius Tech Cares Award for the third consecutive year.
  • The TrustRadius Best Software List celebrates products that support the evolution of self-serve buyers by sourcing and using customer reviews.
  • "Vena Solutions was selected for the 2022 Best Software List as best suited for mid-sized and enterprise businesses," said Megan Headley, Vice President of Research at TrustRadius.
  • Vena Complete Planning automates planning processes across departments and systems in human resources, marketing and sales, each of which can benefit from enterprise performance management (EPM) for forecasting, budgeting and reporting, revenue planning, workforce planning, scenario analysis and beyond.